Adverum Biotechnologies (ADVM) Earns Daily News Impact Rating of 0.08

Media headlines about Adverum Biotechnologies (NASDAQ:ADVM) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Adverum Biotechnologies earned a daily sentiment score of 0.08 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.7409216139423 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Adverum Biotechnologies (NASDAQ:ADVM) remained flat at $$3.05 during trading hours on Monday. 1,439,800 shares of the company’s stock were exchanged, compared to its average volume of 260,898. Adverum Biotechnologies has a fifty-two week low of $2.40 and a fifty-two week high of $4.20.

Adverum Biotechnologies (NASDAQ:ADVM) last posted its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.03). The business had revenue of $0.46 million during the quarter. Adverum Biotechnologies had a negative net margin of 3,398.29% and a negative return on equity of 26.60%. analysts anticipate that Adverum Biotechnologies will post -1.31 earnings per share for the current fiscal year.

Several equities analysts recently commented on ADVM shares. ValuEngine lowered Adverum Biotechnologies from a “sell” rating to a “strong sell” rating in a report on Thursday, November 9th. Raymond James Financial started coverage on Adverum Biotechnologies in a report on Thursday, October 12th. They issued an “outperform” rating and a $6.00 target price on the stock. Zacks Investment Research lowered Adverum Biotechnologies from a “buy” rating to a “hold” rating in a report on Tuesday, September 26th. Finally, Chardan Capital reissued a “hold” rating and issued a $3.50 target price on shares of Adverum Biotechnologies in a report on Tuesday, September 5th.

ILLEGAL ACTIVITY WARNING: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at

About Adverum Biotechnologies

Adverum Biotechnologies, Inc, formerly Avalanche Biotechnologies, Inc, is a gene therapy company. The Company is engaged in discovering and developing medicines to patients suffering from chronic or debilitating disease. The Company operates and manages its business in the segment of developing and commercializing gene therapeutics.

Insider Buying and Selling by Quarter for Adverum Biotechnologies (NASDAQ:ADVM)

Receive News & Ratings for Adverum Biotechnologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adverum Biotechnologies Inc and related companies with's FREE daily email newsletter.

Leave a Reply